Sarepta Therapeutics Inc (SRPT) was Initiated by Credit Suisse to “Outperform” and the brokerage firm has set the Price Target at $68. Credit Suisse advised their investors in a research report released on Oct 18, 2016.
Many Wall Street Analysts have commented on Sarepta Therapeutics Inc. Company shares were Reiterated by Wedbush on Oct 10, 2016 to “Outperform”, Firm has raised the Price Target to $ 72 from a previous price target of $66 .Company shares were Reiterated by RBC Capital Mkts on Sep 28, 2016 to “Outperform”, Firm has raised the Price Target to $ 108 from a previous price target of $83 .Company shares were Reiterated by Needham on Sep 20, 2016 to “Buy”, Firm has raised the Price Target to $ 81 from a previous price target of $47 .
On the company’s financial health, Sarepta Therapeutics Inc reported $-1.19 EPS for the quarter, beating the analyst consensus estimate by $ 0.02 according to the earnings call on Jul 19, 2016. Analyst had a consensus of $-1.21.Analysts expectations of $ .10.During the same quarter in the previous year, the company posted $-0.87 EPS.
Sarepta Therapeutics Inc closed down -1.91 points or -3.52% at $52.28 with 20,24,552 shares getting traded on Friday. Post opening the session at $54.34, the shares hit an intraday low of $52.15 and an intraday high of $55.02 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.
In a different news, on Sep 30, 2016, Shamim Ruff (SVP, Regulatory Affairs & Qual) sold 7,311 shares at $60.00 per share price. According to the SEC, on Sep 26, 2016, Edward M. Md Kaye (President, CEO & CMO) sold 40,179 shares at $60.00 per share price. On Sep 26, 2016, David T Howton (SVP, General Counsel) sold 7,000 shares at $60.00 per share price, according to the Form-4 filing with the securities and exchange commission.
Sarepta Therapeutics Inc. is a biopharmaceutical company. The Company is focused on the discovery and development of unique ribonucleic acid (RNA-targeted therapeutics for the treatment of rare infectious and other diseases. The Company is primarily focused on advancing the development of its potentially disease-modifying Duchenne Muscular Dystrophy (DMD) drug candidates including its lead DMD product candidate eteplirsen which is an antisense PMO therapeutic in Phase III clinical development for the treatment of individuals with DMD who have an error in the gene coding for dystrophin that is amenable to skipping exon 51. The Company is also developing therapeutics using its technology for the treatment of drug-resistant bacteria and infectious rare and other human diseases.